Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Sale of Business

A reconciliation of the accounting for the Company’s Pharma Solutions business in 2023 and 2022 is as follows:

	Gain (loss) on Sale
	2023			2022
Purchase price	$	-		$	7,000
Earnout received		-			1,043
Working capital adjustment, net		(117	)		(766	)
Less: transaction costs		-			(307	)
Total net consideration	$	(117	)	$	6,970
Assets and liabilities disposed of, net (1)		-			(6,970	)
Gain (loss) on sale	$	(117	)	$	-

(1) includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $8.4 million and the write-down of intangible assets was approximately $3.8 million.

Schedule of Components of Assets and Liabilities and Revenue Classified as Discontinued Operations

The components of assets and liabilities classified as discontinued operations consist of the following as of December 31, 2023 and December 31, 2022:

	December 31,		December 31,
	2023		2022
Accrued salary and bonus	$	-	$	92
Other (1)		660		766
Current liabilities of discontinued operations		660		858

(1) Includes $660 and $766 of liabilities related to the former Commercial Services business unit for the periods ending December 31, 2023 and December 31, 2022, respectively.

The table below presents the significant components of its former Pharma Solutions and Commercial Services business units’ results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2023 and 2022.

	For The Years Ended
	December 31,
	2023			2022
Revenue, net	$	-		$	5,678
Loss from discontinued operations		(43	)		(15,968	)
Income tax expense		267			125
Loss from discontinued operations, net of tax	$	(310	)	$	(16,093	)